The pain program COZY - a unique concept for the treatment of chronic pain

Chronic pain is a global scourge that causes enormous human suffering and astronomical costs to society. CombiGene and its partner Zyneyro aim to develop an effective pain treatment that is non-addictive and that does not result in tolerance development.

The pain program COZY

Pain is one of the biggest challenges in healthcare

Between 6 and 8 % of the world's adult population suffers from severe chronic pain.

Huge costs for society

Annual medical and indirect costs of various diseases in the United States.

Pain: USD 635 billion
0%
Cardiovascular diseases: USD 309 billion
0%
Cancer: USD 243 billion
0%
Diabetes: USD 188 billion
0%

Source: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Appendix C. The Economic Cost of Pain in the US. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Washington (DC): National Academies Press (US); 2011

Today's pharmaceuticals are insufficient

The problem with today's treatments is that they are not specifically developed to treat chronic pain. The pain relief that is achieved therefore often has a number of debilitating side effects such as substance abuse problems, depression, anxiety, fatigue, reduced physical and mental ability.

COZY01

Peptide treatment of severe chronic pain

The peptide treatment has shown positive effects in various preclinical models. The continued development will focus on conducting the necessary preclinical studies as quickly and efficiently as possible to evaluate safety and toxicology.
Read more

COZY02

Gene therapy treatment for severe chronic pain conditions

A prototype of the AAV vector that acts as a carrier of the genetic material in gene therapy has been developed by Zyneyro and tested in several preclinical models with very good and long-lasting effect. 
Read more

The epilepsy project – CG01

CG01 is an AAV-based gene therapy with the potential to improve the quality of life for patients with drug-resistant focal epilepsy for whom there is currently no effective treatment

Read more

Latest news

CombiGene announces new preclinical research results in the epilepsy project

Read more

Interim report January – June 2024 for CombiGene AB (publ)

Read more

Stock information

Financial reports

Interim report January – June 2024 for CombiGene AB (publ)

Read more

Interim report January – March 2024 for CombiGene AB (publ)

Read more
  • INGENEIOUS News

An exciting autumn is ahead of us

Read the newsletter

License agreement with Spark Therapeutics

Read the newsletter

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282

Grants

The peptide-based pain project COZY01 has received funding from the Eurostars-3 programme, co-financed by the European Union's research and innovation programme Horizon Europe. Project ID: 4408

CombiGene is a member of ATMP Sweden, for more information visit https://atmpsweden.se/

Memberships

CombiGene is supporting CCRM Nordic and Jan Nilsson is chairman of the Board of Directors.

Academic collaborations

Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School. The pain program COZY originates from academic research at Copenhagen University.